Pharmigene

Pharmigene Dividend

Dividend of Pharmigene (7595.TWO) as of Nov 14, 2026.

Dividend

0.00TWD

Last updated:

How much dividend does Pharmigene 2026 pay?

According to the latest status from November 2026, Pharmigene paid a total of 0.00 TWD per share in dividends within the last 12 months. With the current Pharmigene price of 8.39 TWD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Pharmigene Dividends

Historical Pharmigene Dividends
PaydateDividend

The Pharmigene Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2018
0.00 TWD
Jan 1, 2019
0.00 TWD
Jan 1, 2020
0.00 TWD
Jan 1, 2021
0.00 TWD
Jan 1, 2022
0.00 TWD
Jan 1, 2023
0.00 TWD
Jan 1, 2024
0.00 TWD
Jan 1, 2025
0.00 TWD
The Pharmigene Dividend history
YEARDividendYoY
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—

Is the Pharmigene Dividend Safe?

Pharmigene has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Pharmigene's Dividend Distributions

Pharmigene’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Pharmigene's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Pharmigene's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Pharmigene’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Pharmigene Stock analysis

What does Pharmigene do? Pharmigene, Inc. generates revenue through the manufacturing and sale of pharmaceutical genetic diagnostic products, including AutoEx16 automatic nucleic acid extractors, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kits, and SGE 1502, SGE 3101, SGE 5701, Sega 5801, SGE B27, and SGE whole blood calculation and extraction kits. The company offers molecular diagnostic products and testing services such as drug genetic testing, functional medical testing, and personalized genetic testing. Its primary market is Taiwan, with additional presence in other markets. The firm focuses on genomics science for precision medicine, targeting research and development in drug genomics. Pharmigene's product portfolio includes specialized kits for drug genetic testing, such as the Clopidogrel test kit, which assesses genetic variations affecting drug efficacy. The SGE test suites and kits are designed for various diagnostic applications, including whole blood processing and genetic analysis. The company distributes these products through its established market channels in Taiwan and other regions, emphasizing professional solutions for precision medicine. The firm's testing services cater to healthcare providers and research institutions seeking tailored genetic insights. The company's revenue streams are derived from the direct sale of diagnostic kits, testing services, and overall solutions for drug genomics research. Its target segments include healthcare providers, research institutions, and precision medicine developers in Taiwan and other markets. Pharmigene's focus on genetic diagnostic technologies positions it within the niche of pharmaceutical genomics, serving clients who require advanced molecular diagnostics for personalized healthcare approaches. Pharmigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmigene stock

Pharmigene paid dividends every year for the past 0 years.

Pharmigene is assigned to the 'Health' sector.

The dividends of Pharmigene are distributed in TWD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Pharmigene